Mild cognitive impairment
Mild cognitive impairment means thinking changes are noticeable on testing, but everyday independence is largely preserved. Some people later develop dementia. Others stay stable or improve.
Overview
MCI is a clinical state, not a single disease. When biomarkers support Alzheimer’s pathology, some people become eligible for early-stage antibody discussions. Many people with MCI do not have Alzheimer’s disease. Lifestyle, sleep, mood, medicines, and hearing all deserve attention. Conversion numbers vary by clinic versus community samples.
Subtypes & biomarkers
topDated changes read from the records linked to this diagnosis: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
All 1 changes by month →What is in development for Mild cognitive impairment, drawn from the whole corpus: 2 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this diagnosis, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Technologies being tested · 1
Ideas not yet in a trial · 1
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Who & centres
topOrganisations and centres
This atlas lists sourced companies, institutions, and public figures — not a “see this doctor” directory. Start from Who or the institutions index, and ask the person’s clinical team about a memory clinic referral.
No institutions are linked to this diagnosis yet.
For urgent help and helplines, see resources.
Questions to ask
topQuestions to ask your clinician about Mild cognitive impairment
Newly diagnosed
- What is my exact diagnosis, and which assessments established it?Why: Care plans follow from an accurate diagnosis and how it was confirmed.
- Is genetic testing recommended for me or my family, and what counselling comes with it?Why: Inherited variants can change counselling and, rarely, care; they matter for relatives too.
Any stage
- Would a second opinion at a memory clinic or specialist centre change anything, and can you help arrange it?Why: Complex or high-stakes decisions benefit from a centre that sees many similar patients.
- What supportive care (symptom control, carer support, nutrition, exercise, mental health, financial help) is available from the start?Why: Supportive care improves quality of life and helps people stay on a plan that fits them.
Start from the care guide for household next steps, and use resources for helplines.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.
Direct links plus the targets, companies, and technologies of this diagnosis's products.
technologies
1targets
1drugs
2companies
3terms
1ideas
1Latest papers
topQuery for this diagnosis: (TITLE:"Mild cognitive impairment" OR ABSTRACT:"Mild cognitive impairment") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Mild cognitive impairment, not a curated reading list.
Similar pages
not linked directly; found by shared links- BottleneckLate and uneven diagnosis
Shares Blood test before PET or lumbar puncture, Dementia (umbrella), Alzheimer’s disease and the tag dementia-atlas.
- TechnologyApoE testing
Shares Donanemab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- RoadmapAnti-amyloid medicines
Shares Blood test before PET or lumbar puncture, Donanemab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- TechnologyAnti-amyloid antibodies
Shares Donanemab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- TermARIA
Shares Donanemab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- IdeaAntibody trials that enrol mixed and comorbid disease
Shares Donanemab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- TargetAmyloid-beta
Shares Donanemab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- TrialTRAILBLAZER-ALZ 2
Shares Donanemab, Alzheimer’s disease and the tag dementia-atlas.